MX2016005232A - Formulaciones liposomicas para inhalacion, modificadas con agente tensoactivo, que proveen un perfil de liberacion tanto inmediata como sostenida. - Google Patents

Formulaciones liposomicas para inhalacion, modificadas con agente tensoactivo, que proveen un perfil de liberacion tanto inmediata como sostenida.

Info

Publication number
MX2016005232A
MX2016005232A MX2016005232A MX2016005232A MX2016005232A MX 2016005232 A MX2016005232 A MX 2016005232A MX 2016005232 A MX2016005232 A MX 2016005232A MX 2016005232 A MX2016005232 A MX 2016005232A MX 2016005232 A MX2016005232 A MX 2016005232A
Authority
MX
Mexico
Prior art keywords
immediate
surfactant
sustained release
inhaled
release profile
Prior art date
Application number
MX2016005232A
Other languages
English (en)
Inventor
Cipolla David
Gonda Igor
Original Assignee
Aradigm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aradigm Corp filed Critical Aradigm Corp
Publication of MX2016005232A publication Critical patent/MX2016005232A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biophysics (AREA)

Abstract

Se describen métodos de formulación y composiciones de productos liposómicos de liberación inmediata y sostenida, que comprenden un agente tensoactivo que interacciona con liposomas para afectar la liberación de un fármaco de los mismos, y el suministro de este para el tratamiento de infecciones del aparato respiratorio y otras afecciones, y dispositivos y formulaciones usadas en relación con los mismos.
MX2016005232A 2013-10-22 2014-10-03 Formulaciones liposomicas para inhalacion, modificadas con agente tensoactivo, que proveen un perfil de liberacion tanto inmediata como sostenida. MX2016005232A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361894165P 2013-10-22 2013-10-22
US201461949032P 2014-03-06 2014-03-06
PCT/US2014/059092 WO2015061025A1 (en) 2013-10-22 2014-10-03 Inhaled surfactant-modified liposomal formulations providing both an immediate and sustained release profile

Publications (1)

Publication Number Publication Date
MX2016005232A true MX2016005232A (es) 2017-01-19

Family

ID=52826391

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005232A MX2016005232A (es) 2013-10-22 2014-10-03 Formulaciones liposomicas para inhalacion, modificadas con agente tensoactivo, que proveen un perfil de liberacion tanto inmediata como sostenida.

Country Status (7)

Country Link
US (1) US9987227B2 (es)
EP (1) EP3060198A4 (es)
JP (1) JP2016534155A (es)
AU (1) AU2014340568B2 (es)
CA (1) CA2923647A1 (es)
MX (1) MX2016005232A (es)
WO (1) WO2015061025A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5324223B2 (ja) 2005-12-08 2013-10-23 トランセイブ， インク． 肺感染症を治療する抗感染薬の脂質ベースの組成物及びその使用法
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
MX2015006681A (es) 2012-11-29 2016-04-06 Insmed Inc Formulaciones de vancomicina estabilizadas.
US9532986B2 (en) 2014-04-08 2017-01-03 Aradigm Corporation Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria
SMT202000516T1 (it) 2014-05-15 2020-11-10 Insmed Inc Metodi per trattamento di infezioni micobatteriche polmonati non tubercolari
US12364661B2 (en) * 2015-11-20 2025-07-22 The Regents Of The University Of California Deformable nano-scale vehicles (DNVS) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
JP7280624B2 (ja) 2017-04-03 2023-05-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 経血液脳関門的、経粘膜的及び経皮的薬物送達のための変形可能なナノスケールビヒクル（ｄｎｖ）
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
US20210113595A1 (en) * 2018-04-30 2021-04-22 Purdue Research Foundation Liposomal nano formulation of combinational antibiotics and the uses thereof
WO2019213398A1 (en) 2018-05-02 2019-11-07 Insmed Incorporated Methods for the manufacture of liposomal drug formulations
JP6426873B1 (ja) * 2018-08-06 2018-11-21 積水メディカル株式会社 マイコプラズマ・ニューモニエの免疫学的検出方法
WO2020040818A1 (en) * 2018-08-23 2020-02-27 Qrumpharma Inc. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
GB201814959D0 (en) 2018-09-14 2018-10-31 Secr Defence Methods for the preparation of a pharmaceutical-vesicle formulation and associated products and uses
JP2022521600A (ja) * 2019-02-22 2022-04-11 シラ セラピューティック インコーポレイティッド 吸入可能な治療剤
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759057B1 (en) 1986-06-12 2004-07-06 The Liposome Company, Inc. Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
US5006343A (en) 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
US6623671B2 (en) 1990-10-05 2003-09-23 Royden M. Coe Liposome extrusion process
WO1992014447A1 (en) 1991-02-14 1992-09-03 Baxter International Inc. Binding of recognizing substances to liposomes
US6890555B1 (en) 1992-02-05 2005-05-10 Qlt, Inc. Liposome compositions of porphyrin photosensitizers
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
CA2101241C (en) 1993-07-23 1998-12-22 Jonathan P. Wong Liposome-encapsulated ciprofloxacin
EP0678017B1 (en) 1993-11-05 1998-04-01 Amgen Inc. Liposome preparation and material encapsulation method
US5972379A (en) 1995-02-14 1999-10-26 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering a quinolone
EP0825852B1 (en) 1995-04-18 2004-07-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposome drug-loading method and composition
US5902604A (en) * 1995-06-06 1999-05-11 Board Of Regents, The University Of Texas System Submicron liposome suspensions obtained from preliposome lyophilizates
US5643599A (en) * 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
WO1997035561A1 (en) 1996-03-28 1997-10-02 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved liposome compositions
CA2174803C (en) 1996-04-23 2000-07-11 Jonathan P. Wong Use of liposome encapsulated ciprofloxacin as an immunotherapeutic drug
GB9609779D0 (en) 1996-05-10 1996-07-17 Univ Bruxelles Freeze dried liposome encapsulated amphiphilic drug compositions and a process for the preparation thereof
US6770291B2 (en) 1996-08-30 2004-08-03 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
CA2215716C (en) 1997-09-17 1999-12-07 Her Majesty The Queen, In Right Of Canada, As Represented By The Ministe R Of National Defence Aerosol delivery of liposome-encapsulated fluoroquinolone
IL139231A0 (en) 1998-05-27 2001-11-25 Euro Celtique Sa Preparations for the application of anti-inflammatory, especially antiseptic, agents and/or agents promoting the healing of wounds to the lower respiratory tract
ATE397488T1 (de) 1998-11-13 2008-06-15 Heriot William A Vorrichtung zur herstellung von liposomen
US6855296B1 (en) 1998-11-13 2005-02-15 Optime Therapeutics, Inc. Method and apparatus for liposome production
EP1190705A4 (en) 1999-06-24 2009-03-18 Kyowa Hakko Kogyo Kk METHOD FOR REGULATING THE LEAKAGE OF ENCAPSULATED MEDICINES IN LIPOSOMES
US6174878B1 (en) 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
WO2003075889A1 (en) 2002-03-05 2003-09-18 Transave, Inc. An inhalation system for prevention and treatment of intracellular infections
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
US7879351B2 (en) 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
KR101301653B1 (ko) 2002-10-29 2013-08-30 트랜세이브, 인코포레이티드 항감염제의 지속적인 방출
EP1628637A2 (en) * 2003-05-30 2006-03-01 Alza Corporation Method of pulmonary administration of an agent
US20050214224A1 (en) * 2003-11-04 2005-09-29 Nektar Therapeutics Lipid formulations for spontaneous drug encapsulation
US20060280691A1 (en) * 2005-06-13 2006-12-14 University Of Alberta Spray freeze dried liposomal ciprofloxacin powder aerosol drug delivery
EP1906915B1 (en) * 2005-06-17 2017-09-27 Australian Nuclear Science And Technology Organisation Particles having hydrophobic material therein
JP5324223B2 (ja) 2005-12-08 2013-10-23 トランセイブ， インク． 肺感染症を治療する抗感染薬の脂質ベースの組成物及びその使用法
US8268347B1 (en) 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US8071127B2 (en) * 2006-10-24 2011-12-06 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US8119156B2 (en) 2006-10-24 2012-02-21 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US20100310636A1 (en) * 2007-05-09 2010-12-09 Gita Sharma Stearically stabilized unilamilar vesicles, process for preparation thereof and use thereof
EP2410985A2 (en) 2009-03-26 2012-02-01 Pulmatrix, Inc. Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis
WO2011049960A2 (en) 2009-10-21 2011-04-28 Otonomy, Inc. Compositions and methods for the treatment of sinonasal disorders
AU2011314007B2 (en) 2010-09-29 2017-01-19 Pulmatrix, Inc. Cationic dry powders
JP2012118376A (ja) * 2010-12-02 2012-06-21 Nikon Corp カメラボディ、アダプタ及び交換レンズ
WO2012118376A1 (en) * 2011-03-01 2012-09-07 To-Bbb Holding B.V. Advanced active liposomal loading of poorly water-soluble substances
CN102327269B (zh) * 2011-07-14 2012-11-21 海南美大制药有限公司 一种复方头孢克洛药物组合物脂质体固体制剂
WO2013063492A1 (en) * 2011-10-28 2013-05-02 Board Of Regents, The University Of Texas System Novel compositions and methods for treating cancer
US20150224169A1 (en) * 2012-09-06 2015-08-13 Mcmaster University Compounds and methods for selectively targeting cancer stem cells

Also Published As

Publication number Publication date
JP2016534155A (ja) 2016-11-04
EP3060198A4 (en) 2017-06-28
AU2014340568A1 (en) 2016-03-10
WO2015061025A1 (en) 2015-04-30
US9987227B2 (en) 2018-06-05
EP3060198A1 (en) 2016-08-31
CA2923647A1 (en) 2015-04-30
US20150110855A1 (en) 2015-04-23
AU2014340568B2 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
CY1121373T1 (el) Μεθοδος και φαρμακοτεχνικη μορφη για εισπνοη
MX2021000550A (es) Forma de dosis orales de liberacion sostenida de tofacitinib.
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
MX2018002301A (es) Composiciones de glucano y usos de las mismas.
CA2865972C (en) Inhalable dry powders
PH12014502516A1 (en) Formulations and methods for vaginal delivery of antiprogestins
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
EP2670462A1 (en) Intranasal delivery devices
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
MY176176A (en) Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation
IN2013MU03583A (es)
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
MX389399B (es) Una formulación de rapamicina inhalable para el tratamiento de hipertensión pulmonar.
IN2015DN03854A (es)
EP3060198A4 (en) Inhaled surfactant-modified liposomal formulations providing both an immediate and sustained release profile
WO2014007772A3 (en) Inhalation compositions comprising glucose anhydrous
WO2014007770A3 (en) Inhalation compositions comprising corticosteroid and sorbitol
WO2014007781A3 (en) Inhalation compositions
EA201591415A1 (ru) Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии
MX364652B (es) Formulacion farmaceutica que comprende ciclesonida.
IN2014MN02133A (es)
GB201204632D0 (en) Delivery system
EP3010534A4 (en) Pharmaceutical formulations and methods for oral delivery of biologically active ingredient
UA81941U (ru) Способ лечения хронического эндометрита у женщин на этапе прегравидарной подготовки